Matt Kamm, managing director of Artisan Partners, explains why, following their upswing, biotech stocks are still early in a pharmaceutical renaissance which should capture investor attention.
Earlier in 2014, a sharp sentiment swing pressured biotech stocks. Since then, the category has bounced back as a number of positive developments have reinforced investor confidence. Among them was Regeneron Pharmaceuticals' recent approval in the US and EU for a second indication of its macular degeneration drug Eylea - already one of history's strongest new drug launches. Further, the firm announced positive late-stage trial results for its novel cholesterol-lowering drug, and strong mid-stage results for its medicine for allergic conditions such as atopic dermatitis. Investors in R...
To continue reading this article...
Join Investment Week for free
Signup and gain exclusive members-only insights - all free of charge!
- Unlimited access to real-time news, analysis and opinion from the investment industry, including the Sustainable Hub covering fund news from the ESG space
- Get ahead of regulatory and technological changes affecting fund management
- Important and breaking news stories selected by the editors delivered straight to your inbox each day
- Weekly members-only newsletter with exclusive opinion pieces from leading industry experts
- Be the first to hear about our extensive events schedule and awards programmes
